Natco Pharma Limited – Investor Presentation Summary

Key Operational Highlights

  • Consolidated Total Revenue for Q2 FY27 stood at ₹10,194 Mn.
  • Earnings Before Interest Tax Depreciation and Amortization (EBITDA) stood at ₹3,100 Mn with an EBITDA Margin of 30.4% for Q2FY27.
  • Profit After Share of Profit of Associate for Q2FY27 stood at ₹2,026 Mn.
  • Earnings Per Share (EPS) for Q2FY27 stood at ₹11.31 per share.
  • During the quarter, NATCO acquired an additional 13.25% stake in Adcock Ingram Holding Limited, taking the total holdings to 49%.
  • Profit Share From Our Associate Adcock Ingram Holdings Ltd for Q2FY27 Stood at ₹292 Mn.
  • Invested an additional US$16.7 million in eGenesis, Inc. NATCO's Total Investment in eGenesis amounts to US$24.7 million.

Segment-wise Performance

| Revenue Breakup (INR Mn) | Q2FY27 | Q2FY26 | Q1FY27 |

| API Revenue | 613 | 539 | 667 |

| Formulation – Domestic | 1,457 | 1,054 | 1,364 |

| International Formulations (Incl. profit share and subsidiaries) | 6,684 | 11,402 | 4,771 |

| Pharmaceutical Formulations Total Revenue | 8,141 | 12,456 | 6,135 |

| Crop Health Sciences | 610 | 524 | 408 |

| Other operating & non-operating income | 831 | 1,111 | 734 |

| Consolidated Total Revenue | 10,194 | 14,630 | 7,944 |

Financial Highlights

Revenue: ₹10,194 Mn

EBITDA: ₹3,100 Mn

PAT: ₹2,026 Mn

EPS: ₹11.31

Margins: EBITDA Margin* 30.4%

YoY/QoQ comparison: Q2FY27 Revenue of ₹10,194 Mn vs Q2FY26 ₹14,630 Mn and Q1FY27 ₹7,944 Mn. Q2FY27 PAT of ₹2,026 Mn vs Q2FY26 ₹5,179 Mn and Q1FY27 ₹2,065 Mn.

Geographical Revenue Split

Domestic vs Export/Regional Revenue:

Domestic: ₹1,457 Mn (Formulation – Domestic only, % of Total not specified)

International: ₹6,684 Mn (International Formulations, % of Total not specified)

Balance Sheet Snapshot

Not Specified

Capex & Cash Flow Health

Capital Expenditure: Not Specified. Investment activity includes US$16.7 Mn in eGenesis.

Strategic & R&D Initiatives

  • Key Sole FTFs (Para IV) in the pipeline include Kyprolis (Carfilzomib), Imbruvica (Ibrutinib), Zydelig (Idelalisib), Lynparza (Olaparib), Ozempic (Semaglutide pen), Balversa (Erdafitinib), Wegovy (Semaglutide), and Tabrecta (Capmatinib).
  • Key Para IV products in the pipeline (Filing on NCE-1 date) include Eliquis (Apixaban), Ozempic (Semaglutide pen), Lonsurf (Trifluridine/Tipracil), Yondelis (Trabectedin), Calquence (Acalabrutinib), Kyprolis (Carfilzomib), Nurtec (Rimegepant), Jevtana (Cabazitaxel), and Everysdi (Risdiplam Oral Solution).
  • NRC-2694-A: An orally administered small-molecule tyrosine kinase inhibitor for Head and Neck cancer. A Phase 2 clinical trial approved by US FDA; patient recruitment in progress in US and India.
  • eGenesis: Focused on xenotransplantation. First human transplant of a genetically engineered pig kidney in March'24. FDA cleared Phase 1/2/3 clinical study for kidney xenotransplantation; 33-patient trial to commence in early 2027. FDA clearance received for Phase 1/2 clinical study for liver xenotransplantation.
  • Cellogen Therapeutics: Invested US$2 million. Developing CAR-T cell therapies for leukemia and lymphoma and gene therapies for beta-thalassemia and sickle cell disease. First human dosing for Leukemia to begin shortly in India. Received GMP manufacturing approvals in India.
  • Stero Therapeutics: Invested US$1 million. Focused on developing novel therapy for Cushing's syndrome. Conducting pre-clinical animal studies.

Industry Trends & Business Environment

Not Specified

Management Commentary & Growth Outlook

An earnings call to discuss operational and financial performance is scheduled for 13th November 2026 at 4.00 PM IST with Mr. Rajeev Nannapaneni (Vice Chairman and Chief Executive Officer), Mr. Amit Parekh (Chief Financial Officer), Mr. Rajesh Chebiyam (Executive Vice President, Crop Health Sciences), and Mr. Rajeev Menon (Lead, Investor Relations).